Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery
NCT ID: NCT06639659
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
69 participants
INTERVENTIONAL
2024-10-01
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery
NCT02549768
Dexmedetomidine Versus Gabapentin Premedication on the Emergence Agitation After Rhinoplasty
NCT05626998
Regional Nasal Block and Dexmedetomidine in Endoscopic Sinus Surgery
NCT05361642
Infraorbital Nerve Block for Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor
NCT04785222
Dexmedetomidine Different Doses as Adjuvant to Entropy-assisted General Anesthesia During Functional Endoscopy Sinus Surgery.
NCT05226325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
That is why the anesthetic plan must ensure the best possible surgical field visualization and the most adequate analgesia.
Multimodal anesthesia including regional and general anesthesia are obtained to optimize surgical field by decreasing bleeding, reduce pain, promote rapid recovery and potential economic gains for the hospital.
The sphenopalatine ganglion block (SPGB) is considered one of the regional anesthetic techniques that is safe and easy anesthetic procedure used to control bleeding and for postoperative analgesia.
Dexmedetomidine (DEX) has become popular for induced hypotension. It is an α2-adrenoceptor agonist with a sympatholytic and analgesic effect. It provides a unique conscious sedation without respiratory depression. It is used effectively in optimizing surgical field through its hemodynamic stability effect.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group C (control group) (n=23) patients will be operated under general anesthesia.
General Anesthesia (control group)
patients will be operated under general anesthesia including routine protocol for these cases
Group SPGP (n=23) patients will receive ultrasound guided bilateral sphenopalatine block
Sphenopalatine Ganglion Block
patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
Group DEX (n=23) patients will receive dexmedetomidine drug.
Dexmedetomidine
patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sphenopalatine Ganglion Block
patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
Dexmedetomidine
patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
General Anesthesia (control group)
patients will be operated under general anesthesia including routine protocol for these cases
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* sex: males and females.
* Body mass index: 35 kg/m2.
* ASA Physical status: grade Ⅰ-Ⅱ.
Exclusion Criteria
* Any contraindication for regional anesthesia e.g. coagulopathy, infection at site of block and hypersensitivity to any drug used in this study.
* Patients who are known to be drug addict.
21 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig Univesity Hospital
Zagazig, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anthony Cometa M, Zasimovich Y, Smith CR. Percutaneous sphenopalatine ganglion block: an alternative to the transnasal approach. Int J Obstet Anesth. 2021 Feb;45:163-164. doi: 10.1016/j.ijoa.2020.10.002. Epub 2020 Oct 17. No abstract available.
Mantovani G, Sgarbanti L, Indaimo A, Cavallo MA, De Bonis P, Flacco ME, Scerrati A. Effects of a sphenopalatine ganglion block on postcraniotomy pain management: a randomized, double-blind, clinical trial. Neurosurg Focus. 2023 Dec;55(6):E13. doi: 10.3171/2023.9.FOCUS23549.
Hutton M, Brull R, Macfarlane AJR. Regional anaesthesia and outcomes. BJA Educ. 2018 Feb;18(2):52-56. doi: 10.1016/j.bjae.2017.10.002. Epub 2017 Nov 27. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sphenopalatine block in TEPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.